Form D · Biotechnology

i2O Therapeutics, Inc.

Cambridge, MA · CIK 0001782226

Offering snapshot reported Oct 18, 2023 · SEC filing

Reported sold
$3.5M
Offering amount: $3.99M
Investors reported
7
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 18, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 18, 2023Initial$3,500,000No comparison7SEC filing
Oct 11, 2022Initial$33,539,921No comparison17SEC filing
Jan 24, 2022Initial$2,300,000No comparison7SEC filing
Dec 1, 2020Initial$600,000No comparison2SEC filing
Mar 23, 2020Initial$3,200,000No comparison2SEC filing
Jul 11, 2019Initial$800,000No comparison2SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-495121

Source: Form D, filed Oct 18, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Anthony Aiudi Director
Katie Ellias Director
Christopher Gagliardi Director
Kurt Graves Director, Executive
Samir Mitragotri Director, Executive
Mitragotri Mitragotri Director, Executive
Ravi Srinivasan Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
610 Main Street
Cambridge, MA, 02139